The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

Described herein are self-assembling protein molecules for delivering a payload, for example, a toxic anti-cancer agent, a cancer immunotherapy, a toxic anti-cancer agent and a cancer immunotherapy, or an imaging agent, to specific tissues. Examples of self-assembled proteins include clathrin and derivatives of clathrin.

The invention is directed to a body comprising oxides of lanthanides, in particular holmium oxide (Ho.sub.2O.sub.3), which are supported on a sulphur containing carbon based particle and to a process for producing said body.

This disclosure relates to peptides useful for targeting inflamed or distressed tissue and uses related thereto. In certain embodiment, the peptides comprise SEQ ID NO: 1-14, or variants or derivatives thereof. In certain embodiments, peptides disclosed herein are conjugated to a label to detect, measure, or image cardiac tissue useful in the diagnosis of myocarditis. In certain embodiments, the peptides are conjugated to a particle coating for use in ultrasound imaging, MRI, or targeted therapy. In certain embodiments, peptides disclosed herein are conjugated to a drug or a particle containing a drug useful for targeted therapy.

The present invention relates to a magnetic resonance structure with a cavity or a reserved space that provides contrast and the additional ability to frequency-shift the spectral signature of the NMR-susceptible nuclei such as water protons by a discrete and controllable characteristic frequency shift that is unique to each MRS design. The invention also relates to nearly uniform solid magnetic resonance T.sub.2* contrast agents that have a significantly higher magnetic moment compared to similarly-sized existing MRI contrast agents.

The invention discloses non-iodinated radiopaque microbeads that may be used in image guided embolization in a subject ailing with tumor. The non-iodinated radiopaque microbeads include a ceramic material doped with a CT contrast agent or a MRI contrast agent or both. The doped ceramic is blended with a polymer and the blend is electrosprayed to form the radiopaque microbeads. Further the radiopaque microbeads are radiolabeled with a radioactive isotope. Methods of synthesis of the radiopaque microspheres are also disclosed. The non-iodinated radiopaque microbeads with radiolabeling are capable of rendering an imageable computed tomography (CT) contrast or magnetic resonance imaging (MRI) contrast when administered in a subject. Also the microspheres are biodegradable and hence the treatment could be repeated in case of recurrence of the tumor in the subject.

This disclosure relates to peptides useful for targeting inflamed or distressed tissue and uses related thereto. In certain embodiment, the peptides comprise SEQ ID NO: 1-14, or variants or derivatives thereof. In certain embodiments, peptides disclosed herein are conjugated to a label to detect, measure, or image cardiac tissue useful in the diagnosis of myocarditis. In certain embodiments, the peptides are conjugated to a particle coating for use in ultrasound imaging, MRI, or targeted therapy. In certain embodiments, peptides disclosed herein are conjugated to a drug or a particle containing a drug useful for targeted therapy.

Provided are a hydrophilic particle, a method for manufacturing the same, and a contrasting agent using the same. More specifically, the hydrophilic particle according to the inventive concept may include a hydrophobic particle, and an amphiphilic organic dye directly absorbed on a surface of the hydrophobic particle. In this case, the hydrophobic particle includes a center particle, and a hydrophobic ligand covering a surface of the center particle, and the amphiphilic organic dye may be combined to the hydrophobic ligand by a hydrophobic interaction. The hydrophilic particle may have a surface zeta potential lower than a surface zeta potential of the amphiphilic organic dye.

A polymer-free synthesis method is provided for preparation of monodisperse nanostars. The nanostars can be used for treating and imaging cells in in vivo or ex vivo. The modes of treatment include use of a nanostar modified with a photo-activatable drug, which drug is activated by the photo-response of the nanostar to electromagnetic stimulation; use of a nanostar modified with a thermally-activatable drug, which drug is activated by a thermal response of the nanostar to electromagnetic stimulation; and the thermal response of the nanostar itself to electromagnetic stimulation, which can directly or indirectly cause the death of an undesirable cell.

Described herein are self-assembling protein molecules for delivering a payload, for example, a toxic anti-cancer agent, a cancer immunotherapy, a toxic anti-cancer agent and a cancer immunotherapy, or an imaging agent, to specific tissues. Examples of self-assembled proteins include clathrin and derivatives of clathrin.